Evidence map›Paper›PMID 38633036›Full record

ReviewNanoscale advances2024

Recent advances of nanoparticles on bone tissue engineering and bone cells.

Gejing Zhang, Chenxiao Zhen, Jiancheng Yang, Jianping Wang, Shenghang Wang, Yanwen Fang, Peng Shang

Abstract readReview
In one paragraph

Review in Nanoscale advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Efficacy of SrScientific reports · 2026
    Article
  5. Article
  6. FeBioengineering (Basel, Switzerland) · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Advancing Nanomedicine: For Bone Defect Repair and Regeneration.International journal of nanomedicine · 2025
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gejing ZhangSchool of Life Sciences, Northwestern Polytechnical University Xi'an Shaanxi 710072 China.
Chenxiao ZhenSchool of Life Sciences, Northwestern Polytechnical University Xi'an Shaanxi 710072 China.
Jiancheng YangDepartment of Osteoporosis, Honghui Hospital, Xi'an Jiaotong University Xi'an 710054 China.
Jianping WangSchool of Life Sciences, Northwestern Polytechnical University Xi'an Shaanxi 710072 China.
Shenghang WangSchool of Life Sciences, Northwestern Polytechnical University Xi'an Shaanxi 710072 China.
Yanwen FangHeye Health Technology Co., Ltd Huzhou 313300 China.
Peng ShangResearch & Development Institute of Northwestern Polytechnical University Shenzhen 518057 China shangpeng@nwpu.edu.cn.ORCID https://orcid.org/0000-0001-5418-6240

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the development of biotechnology, biomaterials have been rapidly developed and shown great potential in bone regeneration therapy and bone tissue engineering. Nanoparticles have attracted the attention of researches and have applied in various fields especially in the biomedical field as the special physicochemical properties. Nanoparticles were found to regulate bone remodeling depending on their size, shape, composition, and charge. Therefore, in-depth research was necessary to provide the basic support to select the most suitable nanoparticles for bone relate diseases treatment. This article reviews the current development of nanoparticles in bone tissue engineering, focusing on drug delivery, gene delivery, and cell labeling. In addition, the research progress on the interaction of nanoparticles with bone cells, focusing on osteoblasts, osteoclasts, and bone marrow mesenchymal stem cells, and the underlying mechanism were also reviewed. Finally, the current challenges and future research directions are discussed. Thus, detailed study of nanoparticles may reveal new therapeutic strategies to improve the effectiveness of bone regeneration therapy or other bone diseases.

Identifiers

PMID38633036
PMCPMC11019495

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.